Last updated on March 2019

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)


Brief description of study

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.

II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.

IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE

STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes.

STEPS 1, 3, 5, 7 (Treatment): Patients are assigned to 1 of 30 treatment subprotocols based on molecularly-defined subgroup. (See Arms Section)

STEPS 2, 4, 6 (Screening): Patients experiencing disease progression on the prior Step treatment or who could not tolerate the assigned treatment undergo review of their previous biopsy results to determine if another treatment is available or undergo another biopsy. Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy.

STEP 8 (Optional Research): Consenting patients undergo end-of-treatment biopsy and collection of blood samples for research purposes.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Clinical Study Identifier: NCT02465060

Contact Investigators or Research Sites near you

Start Over

Dana Zakalik

Michigan Cancer Specialists
Roseville, MI United States
  Connect »

Philip J. Stella

Advanced Breast Care Center PLLC
Warren, MI United States
2.44miles
  Connect »

Philip J. Stella

Bhadresh Nayak MD PC-Warren
Warren, MI United States
3.06miles
  Connect »

Philip J. Stella

Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, MI United States
3.06miles
  Connect »

Philip J. Stella

Macomb Hematology Oncology PC
Warren, MI United States
3.06miles
  Connect »

Philip J. Stella

Michigan Breast Specialists-Warren
Warren, MI United States
3.06miles
  Connect »

Philip J. Stella

Saint John Macomb-Oakland Hospital
Warren, MI United States
3.06miles
  Connect »

Philip J. Stella

Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, MI United States
5.05miles
  Connect »

Dana Zakalik

Premier Hematology Oncology Care
Sterling Heights, MI United States
5.05miles
  Connect »

Philip J. Stella

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Philip J. Stella

Lymphoma Clinic of Michigan
Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Philip J. Stella

Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Philip J. Stella

Ascension Saint John Hospital
Detroit, MI United States
5.61miles
  Connect »

Ding Wang

Henry Ford Macomb Hospital-Clinton Township
Clinton Township, MI United States
8.18miles
  Connect »

Dana Zakalik

William Beaumont Hospital-Grosse Point
Grosse Pointe, MI United States
8.23miles
  Connect »

Dana Zakalik

Mitchell Folbe MD PC
Sterling Heights, MI United States
8.97miles
  Connect »

Philip J. Stella

Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, MI United States
9.94miles
  Connect »

Philip J. Stella

Michigan Breast Specialists-Macomb Township
Macomb, MI United States
9.94miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.